Sequoia Financial Advisors LLC Acquires 55,627 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Sequoia Financial Advisors LLC raised its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 2,775.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 57,631 shares of the medical research company's stock after purchasing an additional 55,627 shares during the quarter. Sequoia Financial Advisors LLC's holdings in IQVIA were worth $13,335,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in IQV. Norges Bank purchased a new stake in shares of IQVIA in the fourth quarter valued at about $408,232,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in IQVIA by 1,852.5% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,066,764 shares of the medical research company's stock worth $423,466,000 after buying an additional 1,960,914 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in IQVIA by 19.1% during the second quarter. Alliancebernstein L.P. now owns 5,942,761 shares of the medical research company's stock worth $1,335,754,000 after buying an additional 952,850 shares in the last quarter. AMF Tjanstepension AB purchased a new stake in IQVIA during the third quarter worth about $148,096,000. Finally, Eagle Asset Management Inc. acquired a new position in IQVIA during the third quarter worth about $102,982,000. Hedge funds and other institutional investors own 89.62% of the company's stock.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 1,000 shares of IQVIA stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the sale, the insider now directly owns 20,836 shares in the company, valued at approximately $5,031,894. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other IQVIA news, insider Eric Sherbet sold 1,000 shares of the business's stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $241.50, for a total transaction of $241,500.00. Following the sale, the insider now directly owns 20,836 shares in the company, valued at approximately $5,031,894. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ari Bousbib sold 31,678 shares of the business's stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the sale, the insider now owns 796,752 shares in the company, valued at $199,610,278.56. The disclosure for this sale can be found here. Insiders have sold a total of 41,285 shares of company stock worth $10,331,003 in the last ninety days. 1.60% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Guggenheim cut shares of IQVIA from a "buy" rating to a "neutral" rating in a research report on Thursday, February 15th. SVB Leerink started coverage on shares of IQVIA in a research report on Monday, February 26th. They issued an "outperform" rating and a $290.00 price objective for the company. StockNews.com raised shares of IQVIA from a "hold" rating to a "buy" rating in a research report on Friday, February 16th. Robert W. Baird boosted their price objective on shares of IQVIA from $226.00 to $251.00 and gave the company a "neutral" rating in a research report on Thursday, February 15th. Finally, BTIG Research initiated coverage on shares of IQVIA in a research report on Tuesday, February 13th. They issued a "buy" rating and a $285.00 price objective for the company. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $256.80.

IQVIA Stock Performance

Shares of IQVIA stock traded down $5.92 during trading hours on Wednesday, reaching $239.41. The company's stock had a trading volume of 532,832 shares, compared to its average volume of 988,761. The company's 50 day simple moving average is $242.47 and its 200 day simple moving average is $220.25. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.86 and a current ratio of 0.86. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73. The stock has a market cap of $43.45 billion, a P/E ratio of 32.84, a price-to-earnings-growth ratio of 2.34 and a beta of 1.50.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, beating the consensus estimate of $2.82 by $0.02. The firm had revenue of $3.87 billion for the quarter, compared to the consensus estimate of $3.80 billion. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. IQVIA's quarterly revenue was up 3.5% compared to the same quarter last year. During the same period last year, the firm posted $2.54 EPS. As a group, analysts expect that IQVIA Holdings Inc. will post 10.11 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.